Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
Transl Vis Sci Technol. 2022 Feb 1;11(2):14. doi: 10.1167/tvst.11.2.14.
To assess the measurement properties of the Attitudes to Gene Therapy for the Eye (AGT-Eye) instrument among Australian adults with inherited retinal diseases (IRDs) and parents/caregivers of people with IRDs. Constructs of interest included sources of information, knowledge of treatment methods, awareness of treatment outcomes, and perceived value of gene therapy for IRDs.
A cross-sectional, self-reported, 30-item questionnaire was administered in English from January to June 2021. It was predominantly conducted online with phone and paper alternatives available. Rating scale models were generated separately for each of the four subscales to assess fit, discrimination, and differential item functioning of the items, as well as targeting, reliability, and precision of the subscales. Principal components analysis was used to assess dimensionality.
Responses from 681 participants (87.1% online, 12.9% phone/mail) were included (ages 18-93 years; 51.7% female). Removal of two poorly performing items slightly improved subscale properties. Item reliability was high for each of the subscales; however, person reliability was suboptimal, with limited ability to stratify participants according to traits (person separation coefficient < 1.8 for each subscale). There was no evidence of differential item functioning by gender, online completion, or patient/caregiver status. Evidence of multidimensionality was detected for two subscales.
Four subscales of the AGT-Eye will be used to analyze operational knowledge and perceived value of ocular gene therapy in Australia. Measurement properties may be improved with the generation of additional items.
Physicians can use the AGT-Eye to assess knowledge and expectations of potential recipients of ocular gene therapy for IRDs.
评估澳大利亚遗传性视网膜疾病(IRDs)患者及其家属对眼部基因治疗态度量表(AGT-Eye)的测量特性。感兴趣的结构包括信息来源、治疗方法知识、治疗结果意识以及基因治疗对 IRDs 的预期价值。
2021 年 1 月至 6 月,采用英语进行横断面、自我报告的 30 项问卷。主要通过在线进行,同时提供电话和纸质选项。为每个四个子量表分别生成了评分量表模型,以评估项目的拟合度、区分度和差异项目功能,以及子量表的针对性、可靠性和精密度。主成分分析用于评估维度。
共纳入 681 名参与者(87.1%在线,12.9%电话/邮件)的回复(年龄 18-93 岁;51.7%女性)。删除两个表现不佳的项目略微改善了子量表的特性。每个子量表的项目可靠性都很高;然而,人员可靠性欠佳,根据特征分层参与者的能力有限(每个子量表的人员分离系数<1.8)。没有证据表明性别、在线完成情况或患者/照顾者身份存在差异项目功能。检测到两个子量表存在多维性。
AGT-Eye 的四个子量表将用于分析澳大利亚眼部基因治疗的操作知识和预期价值。通过生成更多的项目,可以提高测量特性。
医学博士,毕业于清华大学,在国内外期刊发表论文 10 余篇,参与多项国家级科研项目。